key: cord-0864963-jb7e86p4
authors: Xu, Lizhou; Li, Danyang; Ramadan, Sami; Li, Yanbin; Klein, Norbert
title: Facile biosensors for rapid detection of COVID-19
date: 2020-10-01
journal: Biosens Bioelectron
DOI: 10.1016/j.bios.2020.112673
sha: d75f19ea7f78bd6c797ccdc49c96e42a68288116
doc_id: 864963
cord_uid: jb7e86p4

Currently the world is being challenged by a public health emergency caused by the coronavirus pandemic (COVID-19). Extensive efforts in testing for coronavirus infection, combined with isolating infected cases and quarantining those in contact, have proven successful in bringing the epidemic under control. Rapid and facile screening of this disease is in high demand. This review summarises recent advances in strategies reported by international researchers and engineers concerning how to tackle COVID-19 via rapid testing, mainly through nucleic acid- and antibody testing. The roles of biosensors as powerful analytical tools are emphasized for the detection of viral RNAs, surface antigens, whole viral particles, antibodies and other potential biomarkers in human specimen. We critically review in depth newly developed biosensing methods especially for in-field and point-of-care detection of SARS-CoV-2. Additionally, this review describes possible future strategies for virus rapid detection. It helps researchers working on novel sensor technologies to tailor their technologies in a way to address the challenge for effective detection of COVID-19.

Since the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), with the disease referred to as novel coronavirus disease first reported in early January 2020 in Wuhan, China (N. , , the growing trend of infected cases is not yet under control (Chan et al., 2020) ,(C. . COVID-19 was officially announced as a pandemic by the World Health Organisation (WHO) on 11 th March 2020. So far there have been more than 7,823,289 cases confirmed globally, with 431,541 deaths from more than 210 countries and territories as of 15 th June, 2020 (World Health Organization, 2020a). SARS-CoV-2 is the virus strain that causes the respiratory illness COVID-19. SARS-CoV-2 is believed to have zoonotic origins and has close genetic similarity to bat coronaviruses (N. . It is a positive-sense single-stranded RNA virus with approximately 50-200 nm in diameter ( Figure 1A ) . Similar to other coronaviruses, SARS-CoV-2 mainly has four structural proteins, namely, the spike (S), membrane (M), envelop (E), and nucleocapsid (N) proteins, respectively (Wrapp et al., 2020) .

The virus makes full use of S protein to bind to angiotensin-converting enzyme 2 (ACE2) on the human cell surface, to gain entry into a host cell. The N protein holds the viral genome but also involves in the host cellular response to viral infection. S, E, and M proteins together create the viral outer protecting membrane ( Figure 1B ) (Wrapp et al., 2020) . Both proteins (e.g. S protein) and viral RNA can be used as targets for COVID-19 detection. Alternatively, antibodies such as IgM and IgG from patient samples could also be detected for understanding the infection history.

SARS-CoV-2 RNA is detectable 2-3 days before onset of symptoms and can remain up to 25-50 days afterwards, depending on disease severity . Many studies show IgM antibodies start to be detectable around 5-10 days after onset of symptoms and rise rapidly, followed by IgG antibody response closely (Peeling et al., 2020) . These seroconversions are typically within the first 3 weeks with the mean time of 9-11 days after onset of symptoms for total antibodies (10-12 days for IgM and 12-14 days for IgG). RNA level can remain high despite high concentrations of IgM and IgG antibodies in patient blood . These viral infection and immune response studies highlight the detection window for SARS-CoV-2 diagnosis and more importantly, guide the strategic implementation of appropriate types of testing at different infection stages. For example, immune testing can play a big role in tracing symptomatic cases at the middle/late stage of the infection (e.g. 5-10 days after symptom onset). A key message from the WHO in early March is: 'test, test, test' [(World Health Organization, 2020b) ]. Testing especially rapid detection is extremely critical and a powerful way to monitor and manage the pandemic before vaccines or effective drugs become available. Effective detection helps to confirm infected cases with symptoms shown or even when still within the virus incubation period (diagnostic testing), thus allowing treatment on-time. Millions of RNAbased tests have been carried out around the world looking for the presence of viral genes in a nose or throat swab as a sign of active infection. Additionally, blood tests for antibodies to SARS-CoV-2 can indirectly indicate an active infection or post-infection immunity/infection history (surveillance testing). Prompt testing also helps efficient allocation of medical resources in hospitals and saves time for frontline health workers. Particularly for low-income countries, fast, affordable, in-field and point-of-care testing can have substantial effects in controlling the spread of the disease where health systems may be weak and access to medical treatment limited. Furthermore, valuable information about the local distribution of infections enhances the accuracy of epidemiological prediction and facilitates corresponding policymaking. Therefore, rapid, facile, cost-effective and accessible detections for large-scale screening, in-field testing and point-of-care diagnosis of the disease are of great importance and urgency for quickly controlling the highly contagious and rapid spread of COVID-19. In this work, we first review the recent advance in rapid testing for COVID-19. We then highlight the roles of biosensors for rapid and facile detection of SARS-CoV-2 covering viral RNAs, surface antigens/whole viruses, J o u r n a l P r e -p r o o f antibodies and potential biomarkers detection. Finally, future developments of novel virus biosensors are discussed.

Currently, CT imaging, haematology tests and molecular methods based on viral genetic measurements are the primary tools used for clinical diagnosis of COVID-19, together with the identification of clinical symptoms to confirm infection (Y. H. . These laboratory tests are essential to control the burgeoning of the disease. An RNA-based metagenomic nextgeneration sequencing (mNGS) approach was used to identify the sequence of SARS-CoV-2 immediately after the initial outbreak (L. . mNGS is a sensitive technique, but it is restricted by throughput, turnaround time, high cost and a requirement for high technical expertise. Rapid detection approaches could usher in an era of point-of-care testing (POCT) or in-field screening of viruses. Figure 2 shows the two main testing approaches that are currently being used for COVID-19 globally: nucleic acid testing and antibody testing. within 30 min using primers targeting ORF1ab and S (spike) genes, with a LOD of 2 × 10 1 copies and 2 × 10 2 copies of RNA per reaction, respectively . No crossreactivity was found with another 60 respiratory pathogens. The sensitivity (true positive rate) for clinical specimen diagnosis (n=130) was close to 100% (95% CI 92.3%-100%), as was its specificity (95% CI 93.7%-100%). Compared to qRT-PCR, RT-LAMP is faster and does not require prior RNA isolation from the samples. The reagents for RT-LAMP are relatively cheap and stable at room temperature, and therefore this technique holds promise for use outside of a central laboratory (in-field detection) by staff without special training and without need of advanced equipment . A colorimetric-LAMP method was reported using pHsensitive dyes to visualise the LAMP amplification via the change in pH resulting from proton accumulation due to the incorporation of deoxynucleoside triphosphates (dNTPs) (Y. . A sensitivity/LOD as low as 4.8 copies/μL was achieved in testing RNA samples purified from patient respiratory swabs, and the results were in 100% agreement with those from J o u r n a l P r e -p r o o f the qRT-PCR method. This effort expands the toolbox of molecular tests beyond sophisticated diagnostic laboratories in aiming to combat and monitor the growing public health threat.

Additionally, digital PCR (dPCR) has been reported to improve the LOD to at least 10-fold lower than that of RT-PCR, and overall accuracy in the clinical detection of 109 samples was reported to be 96.3%, suggesting the potential of dPCR for the detection of asymptomatic and suspect patients .

J o u r n a l P r e -p r o o f Although RT-PCR tests are sensitive and widely used as current diagnostic tool for SARS-CoV-2, they can only be pursued in certified laboratories with expensive equipment and trained technicians but not in places such as airports, borders, big shopping centres, etc, where testing facilities are not easily accessible. Considering the delivery time of samples to centralised labs, RT-PCR testing could take over 24 h or longer from sampling to results (turnaround time), despite the assay itself taking only a few hours. Additionally, high false negative rates might be an issue for the RT-PCR testing of COVID-19 due to errors in sampling and testing , , . Sometimes the identification of target viral gene sequences cannot confirm the presence of active virus particles, because a positive detection may be due to residues of viral RNA. As summarised in conjugate pad, a nitrocellulose membrane and an absorbent pad. The sample pad is exposed to the sample (a mixture of blood cells, vesicles, cell debris, antibodies, small molecules, etc.) and

acts as a filter to promote lateral aid flow. The sample rehydrates the pre-immobilised goldconjugated recombinant antigen (i.e. spike protein or its receptor binding domain (RBD)) on the conjugate pad and the antibodies bind with their matching antigens. Due to capillary force, the sample continues to flow along the nitrocellulose membrane to reach the test line and the control line. The absorbent pad will absorb excess sample fluid. Colloidal gold nanoparticles are often used for colorimetric visualisation, but coloured latex nanoparticles, fluorophores, etc., can also be used [ (Sajid et al., 2015) ]. ]. However, the specificity was not evaluated for this ICG assay. Nonetheless, according to a multi-centre cross-sectional study, the positive rate for IgG from antibody testing could reach 100% at around 20 days after symptom onset , confirming the strong ability of antibody testing kits for use in late-stage infections. The positive rate of serum IgG single testing has been reported to be higher than that of IgM alone in COVID-19 detection, but the detection of both IgG and IgM was shown to be more accurate (Z. Li et al., 2020) ,(Y. .

Antibody test kits are not yet available for home testing but do allow testing in laboratories or by healthcare workers at a point-of-care. Antibody testing cannot confirm the presence of the virus.

Positive results mean acquired immunity against COVID-19 infection, which might be ascribed to past or present infections with non-SARS-CoV-2 strains such as coronavirus HKU1. In contrast, negative results do not rule out SARS-CoV-2 infection, particularly for those who have been in contact with virus carriers. IgM was found to be detectable in patient's blood after 3-6 days post-infection, with IgG detectable after 8 days , . Hence antibody testing is useful at the intermediate or late stages rather than the early stage of infection . In a word, this rapid screening tool is more suitable as a complementary method to nucleic acid testing (especially for negative results) by providing important immunological evidence for physicians to make diagnostic and pre-treatment decisions, but not as a sole basis for the diagnosis or exclusion of COVID-19 infection (W. . Notably, once a vaccine for COVID-19 is available and people become immunised by vaccination, antibody testing may not be able to differentiate those who acquire immunity from those infected ones. Industries have been active in developing antibody test kits (mostly immunoassays) ( 1 The blood sample is usually in small amount collected from fingertip by "finger-prick". 2 The sensitivity of a clinical test refers to the ability to correctly identify those patient samples (also called the true positive rate) [ (Lalkhen and McCluskey, 2008) ]. 3 The specificity of a clinical test refers to the ability to correctly identify those non-patient samples (also called true negative rate) [ (Lalkhen and McCluskey, 2008) ]. Figure 3C ) . In this biosensor, the DNA nanoscaffolds constructed by the self-assembly of long DNA strands and self-quenching probes 

In addition to rapid detection of viral genetic components in swabs using biosensors, it would be attractive to implement the direct and facile sensing of the whole virus particle or its corresponding surface antigen epitope. This strategy could be employed for the development of a diagnostic or screening tool for COVID-19. There have been some relevant research studies reported so far. For example, an ultrasensitive graphene field-effect transistor (Gr-FET)

immunosensor was reported recently as an effort towards simple and rapid screening for COVID-19 ( Figure 4A ) (X. . The graphene surface was functionalised with SARS-COV-2 spike S1 subunit protein antibody (CSAb) or ACE2 receptor. The hybridization of the slightly positively charged S1 protein (which contains a receptor binding domain, RBD) with the immobilised CSAb/ACE2 receptors alters its conductance/resistance via field effect, which can be electrically read out in a sensitive way. This Gr-FET immunosensor can rapidly identify (in about 2 min) and accurately capture the COVID-19 spike protein S1 at a LOD down to 0.2 pM, in a real-time and label-free manner. Although whole coronavirus particles instead of pure

antigen proteins need to be tested for assay validation, and clinical trials are then required, this work represents an early proof-of-concept study and demonstrated the potential of Gr-FET technology for sensitive and rapid detection of coronaviruses. Interestingly, another field-effect transistor (FET)-based graphene biosensing device coated with a specific antibody against SARS-CoV-2 spike protein has been reported for direct detection of SARS-CoV-2 ( Figure 4B ) (Seo et al., 2020) . The introduced virus particles onto the antibody coated graphene surface generated readable electric changes. This COVID-19 FET sensor not only detects SARS-CoV-2 antigen protein transport medium for swab samples, but also detects cultured viruses and viruses in clinical samples. The LOD for clinical sample detection (n=19 patients and normal subjects) reached 2.42 × 10 2 copies/mL. A larger clinical sample size would be needed to further validate its clinical potential for virus detection. Nevertheless, given the complexity of clinical samples, the development of novel materials for FET sensors which could overcome problems of non-specific interactions and screening effects associated with clinical samples would be necessary to provide more accurate detection. One of the key issues here is high assay sensitivity with a minimum of false alarms, which needs to be achieved in order to facilitate practical applications. Our team has been developing graphene sensors and FET technology for the detection of cells, exosomes, and biomolecules in biofluids over the past few years (Kwong Hong Tsang et al., 2019), (Delle et al., 2018) , (Hanham et al., 2015) . One of our recent work on Gr-FET biosensors for exosome detection can achieve LOD down to single J o u r n a l P r e -p r o o f particle level within 10 min, enhanced by surface nano decoration of specific carbon dots (Ramadan et al., 2020) . Our carbon dot approach has boosted the detection limit for exosomes, and we expect a similar improvement for COVID 19 detection: exosomes exhibit many similar properties to SARS-CoV-2, including equivalent particle size (50~200 nm), abundant surface antigen molecules, shell-core spherical structure, etc. therefore it is theoretically reasonable to repurpose this ultrasensitive technology for COVID-19 detection. Current work focuses on wafer scalable fabrication of Gr-FET sensors towards sensitive, rapid, in-field and cost-effective screening of SARS-CoV-2, by working together with a world-leading graphene foundry (Graphenea, 2010) . with the highest to be 7.11 × 10 8 copy/swab at day 4, first week of symptom onset, and in most cases viral doses in sputum and stool samples are above 10 2 copies per swab, as suggested by a recent virological analysis of 9 patients (Wölfel et al., 2020) . Similar conclusions on viral load were drawn from another clinical study of 17 patients with COVID-19 (Zou et al., 2020) . These data indicate that a biosensor capable of accurately detecting 100 virus particles or more (e.g.

LOD ≤ 10 2 RNA/swab) would be potential as a screening tool, and even as a diagnostic tool. It might also be useful for hospital discharge management, since patients beyond day 10 of symptoms with less than 100 viral RNA copies per μL of sputum could be considered for early discharge and ensuing home isolation (Wölfel et al., 2020) . Obviously it is easier to detect severe COVID-19 cases than mild ones, as the former tend to express higher viral load and longer virus-shedding periods . Hence, desired antigen testing methods are those sensitive enough to detect the low end of clinically relevant viral loads, typically around 10 3 viral nucleic acids per mL (one virion per μL), which is as low as a single particle within one sample, in order to compete with the current RT-PCR diagnostic method whose LOD is as low as 3 copy/μL of input sample (equal to 3 viral particles) (CDC, 2020), (Zou et al., 2020) . Another important issue is the specificity, especially for surface antigen/whole virus detection. Positive results from antigen tests can be highly accurate, but there is a higher chance of false negatives, so negative results do not rule out infection, which may cause severe contagion. Other coronaviruses such as Middle East respiratory syndrome coronavirus (MERS-CoV) and Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) are likely to cause interference in the detection of SARS-CoV-2 due to their similar size, viral structure, and infective properties.

Influenza virus A or B may also affect the selectivity of detection. Therefore, the biorecognition element, usually antibodies or aptamers, should be carefully selected in the design of biosensors and their specific binding with target virus should be well assessed against those potential interferable viruses.

With advance in functional materials, novel sensing mechanisms and nanotechnology, singlevirus analysis would be possible, though still challenging in clinical settings (Schmidt and Hawkins, 2016) . Meanwhile, emerging technical progress would help to overcome other challenging issues such as assay stability and reproducibility for biosensors in antigen/whole J o u r n a l P r e -p r o o f virus detection, thus facilitating accurate screening or diagnosis. SARS-CoV-2 is a spherical particle around 100 nm in diameter, with many antigens expressed on the surface ( Bar-On et al., 2020) . Such properties of the SARS-CoV-2 virus are similar to other viruses such as influenza viruses which researchers are more familiar with and more detection approaches are available.

Therefore ideas to improve COVID-19 detection toward rapid, facile and reliable applications can be inspired by previous research (Schmidt and Hawkins, 2016) , . For example, by working closely with industry partners and clinicians, our team is currently developing a portable graphene sensor for both viral antigen and whole virus detection, adapting from an established point-of-care platform for exosome analysis (Kwong Hong Tsang et al., 2019) , (Ramadan et al., 2020) . Many other biosensing platforms developed for rapid, infield, and portable detection of various viruses by our team over the past decades are promising to be repurposed for SARS-CoV-2. For instance, a target-responsive hydrogel aptasensor embedded with quantum dot fluorescent reporters could be used for rapid, one-step and in-field detection of virus in 30 min (Xu et al., 2016) . A smart bio-nanogate controlled enzymatic biosensor could enhance the sensitivity of virus detection to almost single particle level . Other rapid and in-field technologies including an impedance immunosensor based on low-cost microelectrodes (Lin et al., 2015) (Wang et al., 2011) , an impedance biosensor with gold nanoparticles for signal amplification (Karash et al., 2016) , a facile quartz crystal microbalance biosensor , etc. have demonstrated outstanding capability to sensitively and specifically detect viruses in swab samples and these approaches are highly promising to be developed as portable COVID-19 detection. Aptamers are single-stranded RNA or DNA oligonucleotides capable of selective and sensitive binding to target antigens via hydrogen bonding, electrostatic, and hydrophobic interactions . They represent an alternative to antibodies as virus recognition agents in the design of such novel biosensors. Therefore, testing based on antigen/whole virus holds promise for rapid and facile screening in-field or at point-of-care.

Apart from the reported and commercially available lateral flow test kits for detecting generated antibodies in blood, researchers around the world are intensifying the investigation of new and emerging biosensing technologies for antibody detection. For example, the Gr-FET sensing platform is possible to be developed for screening potential antibody candidates to SARS-CoV-2, if surface antigens like spike proteins are initially coated onto graphene for the sensor design.

Zhang and the co-workers have demonstrated the principle of spike protein S1 antigen functionalized Gr-FETs for fast analysis and screening of neutralizing antibodies, which can block coronaviruses from attaching and infecting the health cell (X. .

Nevertheless, apart from the current lateral flow-based immunoassays which are based on mature industrial platforms, we believe more rapid detection approaches will be developed with the help of nanomaterials, microfluidics, and 3D printing, etc. for effective screening of COVID-19.

Apart from the detection of viral RNA, surface antigen, whole virus particle, and the corresponding antibodies, to detect other novel biomarkers may present an interesting testing strategy. In a recent exploratory study to investigate a diagnostic mechanism based on early traces of mitochondrial reactive oxygen species (ROS) overproduction as lung cells'

dysfunctions induced by SARS-CoV-2, Miripour and coworkers developed a rapid, portable and simple electrochemical sensor for ROS measurement in the sputum sample (with a volume of <500 μL) (Miripour et al., 2020) . This ROS detector system consists of a disposable sensor as the main diagnostic part of the system, an integrated portable automatic electrochemical readout board and a sample holding unit ( Figure 5A) . biomarkers have been identified with homocysteine and angiotensin II, in particular, could play a significant role (Ponti et al., 2020) . In addition, recent studies show individuals with severe COVID-19 may be at risk for cytokine storm syndrome (Mehta et al., 2020) , therefore, point-ofcare methods and biosensors that are capable for monitoring cytokine (e.g. IL-6) levels would J o u r n a l P r e -p r o o f be needed and beneficial for patients suffering from the severe viral inflammation (Russell et al., 2020) . 

To mitigate the global spread of the COVID-19 pandemic, low-cost, fast, reliable, and sensitive detection methods are still in great demand to screen for the disease in field and at point-of-care and for the immunity among large populations. It is of primary importance to diagnose those already showing symptoms (suspects). It is highly desirable to enable the diagnosis of those without any symptoms (asymptomatic carriers), as in those cases the infected viral dose is usually low and they probably represent a sizeable percentage (more than one-third) of total infections (Qiu, 2020) , (Nishiura et al., 2020) . Beyond the screening technologies discussed in this review, a promising and futuristic (albeit not unrealistic) type of fast detection kit for the SARS-CoV-2 and other viral infections can be visualized to be, for example, a small cartridge or chip with a handheld or portable device that would directly detect viral particles in a swab, or even a breath or saliva sample, within a short period of time without pre-treatment or enrichment.

Alternatively, target molecules such as the RNA of the virus could be detected directly, followed J o u r n a l P r e -p r o o f by the simple breakage of the outer viral membrane to release the RNA. As one realistic possibility, single immobilized viral particles could be detected through light scattering, given that their relatively high refractive index resembles that of DNA, and commercial CMOS imaging sensors could be employed to detect single virus particles. To summarize, the criteria now known by the acronym ASSURED (Affordable, Sensitive, Specific, User-friendly, Rapid, Equipment-free, Delivered), as coined by the WHO in 2004, should represent the guidelines to be followed in building a strong health care system (Kettler et al., 2004) . With rapid advances in digital and mobile health technology, so-called REASSURED (Real-time connectivity, Ease of specimen collection, Affordable, Sensitive, Specific, User-friendly, Rapid and Robust, Equipment-free or simple and Environmentally friendly, Deliverable to end-users) diagnostic systems could be established to strengthen health care systems and improve patient outcomes ( Figure 6 ) (Land et al., 2019) . Particularly in low-income and middle-income countries (LMICs) and resource-limited areas without sufficient access to clinical laboratories, the use of point-ofcare molecular assays and rapid immunodiagnostic tests (serology testing) should be recommended without any hesitation for SARS-CoV-2 detection (Peeling et al., 2020) . Both are now commercially available, scalable, and affordable to enable rapid community-based testing for COVID-19 in these LMICs and areas. Global cooperation and international solidarity could empower their capacity and enhance the goods/reagents supply to combat this pandemic. The "REASSURED" biosensors for virus detection as discussed in this review can help triage symptomatic individuals in community settings, test contacts of confirmed cases, and assist in situational analysis and surveillance, providing the methods highly specific for the disease.

J o u r n a l P r e -p r o o f Figure 6 . Schematic diagram of "RESSURED" biosensors for the detection of SARS-CoV-2 including approaches based on targeting viral RNAs, surface antigens, whole viruses, antibodies and other biomarkers in human specimens.

We do not doubt that the COVID-19 pandemic will be fought effectively in the near future.

Lessons to be learned from the shocking number of deaths and huge economic crisis involved should alert us to the need to be well-prepared for any viral or other pathogenic microbial outbreaks in the future. In this context, rapid detection strategies are key to the prevention and management of potential future epidemics. Thus it is even more important and essential to develop lab-independent, hospital-decentralised, personalised, and point-of-care diagnostic approaches with cheap, fast, high-throughput and portable screening. Novel sensors based on functional materials, nanotechnologies and creative sensing mechanisms hold promise in terms of unprecedented sensitivity, minimal size and low cost. Progress in molecular and synthetic biology, the discovery of novel binding agents such as nanobodies and aptamers, and bioengineering may facilitate greater specificity in detection. New smart sensing approaches that combine the ultrahigh sensitivity of biosensors with advances in artificial intelligence and the Internet of Things can help to provide better control of any potential spread of diseases (Jeong et al., 2020) . The present pandemic will clearly contribute to the definition of goals for agendas in interdisciplinary science in the near future.

J o u r n a l P r e -p r o o f

Detect COVID-19 in as Little as 5 Minutes | Abbott Newsroom

Fast SARS-CoV-2 detection by RT-qPCR in preheated nasopharyngeal swab samples

Autobio's two antibody detection kits for SARS-CoV-2 [WWW Document

SARS-CoV-2 (COVID-19) by the numbers

CRISPR-Cas12-based detection of SARS-CoV-2

CDC's Diagnostic Multiplex Assay for Flu and COVID-19 and Supplies | CDC [WWW Document

COVID-19, lgG/lgM rapid test, antibody detection, blood test, serological test, coronavirus disease, lateral flow immunoassay

Xpert® Xpress SARS-CoV-2 has received FDA Emergency Use Authorization [WWW Document

A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster

RNA based mNGS approach identifies a novel human coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Laboratory testing for COVID-19

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

Cue -COVID-19 [WWW Document

ScFv-modified graphenecoated IDE-arrays for 'label-free' screening of cardiovascular disease biomarkers in physiological saline

European Centre for Disease Prevention and Control, 2020. An overview of the rapid test situation for COVID-19 diagnosis in the EU / EEA

CovidNudge: diagnostic accuracy of a novel lab-free point-of-care diagnostic for SARS-CoV-2 1

High quality graphene producer -Graphenea [WWW Document

Dielectric measurements of nanoliter liquids with a photonic crystal resonator at terahertz frequencies

Chapter3: The Vocabulary of Analytical Chemistry

Temporal dynamics in viral shedding and transmissibility of COVID-19

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Ultra-sensitive and high-throughput CRISPR-p owered COVID-19 diagnosis

Continuous on-body sensing for the COVID-19 pandemic : Gaps and opportunities

DNA nanoscaffold-based SARS-CoV-2 detection for COVID-19 diagnosis

Diagnostic value and dynamic variance of serum antibody in coronavirus disease 2019

A rapid advice guideline for the diagnosis and treatment of

Rapid detection of avian influenza virus H5N1 in chicken tracheal samples using an impedance aptasensor with gold nanoparticles for signal amplification

Mapping the landscape of diagnostics for sexually transmitted infections: Key findings and recommandations

Chemically Functionalised Graphene FET Biosensor for the Label-free Sensing of

Clinical tests: Sensitivity and specificity

Rapid detection of novel Coronavirus (COVID-19) by reverse transcription-loop-mediated isothermal amplification. medRxiv 2020.02.19

REASSURED diagnostics to inform disease control strategies, strengthen health systems and improve patient outcomes

Evaluation of nine commercial SARS-CoV-2 immunoassays

Development of an automatic integrated gene detection system for novel severe acute respiratory syndrome-related coronavirus (SARS-CoV2)

Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis

Evaluations of serological test in the diagnosis of 2019 novel coronavirus (SARS-CoV-2) infections during the COVID-19 outbreak

An impedance immunosensor based on low-cost microelectrodes and specific monoclonal antibodies for rapid detection of avian influenza virus H5N1 in chicken swabs

Viral dynamics in mild and severe cases of COVID-19

Antibody responses to SARS-CoV-2 in COVID-19 patients: the perspective application of serological tests in clinical practice

SARS-CoV-2 detection using digital PCR for COVID-19 diagnosis, treatment monitoring and criteria for discharge

COVID-19: consider cytokine storm syndromes and immunosuppression

Accula SARS-CoV-2 diagnostic test for COVID-19 -Mesa Biotech [WWW Document

Real-time diagnosis of reactive oxygen species (ROS) in fresh sputum by electrochemical tracing; correlation between COVID-19 and viral-induced ROS in lung/respiratory epithelium during this pandemic

The impact of biosensing in a pandemic outbreak: COVID-19

15 minute COVID-19 rapid test kit announced -JEMS [WWW Document

Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19)

Serological immunochromatographic approach in diagnosis with SARS-CoV-2 infected COVID-19 patients

Development of reverse transcription loop-mediated isothermal amplification (RT-LAMP) assays targeting SARS-CoV-2

Serology testing in the COVID-19 pandemic response

Biomarkers associated with COVID-19 disease progression

Lateral flow (immuno)assay: Its strengths, weaknesses, opportunities and threats. A literature survey

Dual-Functional Plasmonic Photothermal Biosensors for Highly Accurate Severe Acute Respiratory Syndrome Coronavirus 2 Detection

Covert coronavirus infections could be seeding new outbreaks

Carbon dot (CDs) enhanced graphene field effect transistors for ultrasensitive detection of exosomes

Biosensors for Managing the COVID-19 Cytokine Storm: Challenges Ahead

Designs, formats and applications of lateral flow assay: A literature review

Single-virus analysis through chip-based optical detection

Rapid detection of COVID-19 causative virus (SARS-CoV-2) in human nasopharyngeal swab specimens using field-effect transistor-based biosensor

SARS-CoV-2 Total Assay -Siemens Healthineers USA

SureScreen Diagnostics, 2020. COVID-19 coronavirus rapid test cassette | SureScreen Diagnostics

Dynamic profile of RT-PCR findings from 301 COVID-19 patients in Wuhan, China: a descriptive study

Homogeneous circle-to-circle amplification for real-time optomagnetic detection of SARS-CoV-2 RdRp coding sequence

Rapid COVID-19 diagnostic test developed by Cambridge team to be deployed in hospitals

FDA Combating COVID-19 with Medical Devices

A novel coronavirus outbreak of global health concern

Biosensors for rapid detection of avian influenza

Hydrogel based QCM aptasensor for detection of avian influenza virus

Evaluation study of a portable impedance biosensor for detection of avian influenza virus

Bio-nanogate controlled enzymatic reaction for virus sensing

Selection and J o u r n a l P r e -p r o o f characterization of DNA aptamers for use in detection of avian influenza virus H5N1

Virological assessment of hospitalized patients with COVID-2019

World Health Organization, 2020a. Coronavirus disease (COVID-2019) situation reports -147

WHO Director-General's opening remarks at the media briefing on COVID-19 -16

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Chest CT for Typical 2019-nCoV Pneumonia: Relationship to Negative RT-PCR Testing

Comprehensive serological profiling of human populations using a synthetic human virome

A target-responsive and size-dependent hydrogel aptasensor embedded with QD fluorescent reporters for rapid detection of avian influenza virus H5N1

Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission

Rapid and visual detection of 2019 novel coronavirus (SARS-CoV-2) by a reverse transcription loopmediated isothermal amplification assay

Evaluation of COVID-19 RT-qPCR Test in Multi-Sample Pools

Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes

Electrical probing of COVID-19 spike protein receptor binding domain via a graphene field-effect transistor

Rapid molecular detection of SARS-CoV-2 (COVID-19) virus RNA using colorimetric LAMP. medRxiv 2, 2020.02.26

Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019

A novel coronavirus from patients with pneumonia in China

Multiplex reverse transcription loop-mediated isothermal amplification combined with nanoparticle-based lateral flow biosensor for the diagnosis of COVID-19

SARS-CoV-2 viral load in upper respiratory specimens of infected patients

None of the authors has a financial or personal relationship with other people or organizations that could inappropriately influence or bias the content of this review.